See Whole Prescribing Details OPDIVO® (nivolumab) is indicated for that treatment of Grownup patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed immediately after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin or immediately after three or maybe more strains of systemic therapy that fea… Read More